HemaToxMod HemaTrax: Lineage-resolved prediction of hematotoxicity for human-relevant drug development
- Coordinator
- Universitat Basel, Switzerland
- Runs
- 1 September 2026 to 29 February 2028
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101335316
What the project is doing
In the project's own words, from its summary on CORDIS.
Hematotoxicity is a major determinant of treatment intensity and dosing in cancer therapy and a frequent cause of late-stage attrition in drug development. Current pre-clinical assessment strategies provide limited mechanistic insight into how drugs perturb human hematopoiesis. Animal models often translate poorly to human lineage sensitivities and rely on late aggregate outcomes, such as cytopenias, while human in-vitro assays typically lack bone-marrow niche context.
As a result, lineage-specific toxicity mechanisms remain difficult to anticipate, particularly for complex or combination therapies. This project will test a mechanism-informed framework (HemaTrax) for predicting hematotoxicity. HemaTrax integrates human hematopoietic niche co-culture systems with early lineage-resolved single-cell profiling and computational modelling of gene-regulatory perturbations. Drug-induced changes in transcription-factor activity detected at early differentiation stages will be mapped onto lineage-specific regulatory programmes derived from a large human bone-marrow reference atlas to predict downstream hematopoietic effects.
The main objective is to determine whether early transcription-factor perturbations predict clinically observed hematotoxicity patterns. Model-derived predictions will be systematically benchmarked against longitudinal hematological data from retrospective patient cohorts treated with selected chemotherapeutic agents. If successful, this framework will establish a human-relevant and mechanistically interpretable basis for hematotoxicity assessment, enabling improved pre-clinical decision-making and informing the design of prospective clinical validation studies.
More broadly, the approach supports regulatory efforts to increase human relevance while reducing reliance on animal experimentation.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitat Basel | Basel | Switzerland | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI